# Richard Pazdur
Топ епизоди на подкаста
Актуализирано:
richard pazdur is an American oncologist serving as the founding director of the Oncology Center of Excellence within the Food and Drug Administration. He was appointed to the position in 2005. He was previously the director of the FDA's Office of Hematology Oncology Products from 1999 to 2005.
Massive personnel shortage threatens new Trump plan: analysis
Transcript:After a lengthy delay, President Donald Trump released a national cybersecurity strategy on Friday afternoon — and, as one critic observed, it seems at odds with the reality of America “hemorrhaging cyber-talent.”Trump’s strategy is "impressively underachieving, even by the abysmal stand…
CBER Director Vinay Prasad dared to “say no to drugs”
FDA’s Center for Biologics Evaluation and Research Director Vinay Prasad is set to leave the agency for a second time amid controversy.
In a March 6 post on X, FDA Commissioner Marty Makary suggested that Prasad’s presence at FDA was a “sabbatical” from his academic career and that he would be ret…
Merck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry.
At the latest meeting of the American A…
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the New York pharma. Analysts were more than satisfied with Lilly’s 56% revenue incre…
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the New York pharma. Analysts were more than satisfied with Lilly’s 56% revenue incre…
Beone's Beqalzi FDA Approval Challenges AbbVie | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery.
Starting w…
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA chief of staff and chief AI officer.
Domino effect aside, the reaction from the industry has been mo…
Lilly's Obesity Drug Rivals Surgery: FDA Changes Ahead | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, a domain experiencing profound changes marked by leadership transitions, regulat…
The FDA's Cancer Revolution with Richard Pazdur_e.087
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Richard Pazdur, one of the most influential figures in modern oncology and cancer drug development. As the founding director of the FDA's Oncology Center of Excellence and former director of the Office of Hematology and Oncolog…
Dr. Richard Pazdur on the Future of Cancer Treatment
For more than two decades, Dr. Richard Pazdur helped shape the future of cancer treatment from inside the FDA, overseeing many of the therapies that transformed care for patients around the world. He played a central role in building the FDA's oncology review programs and accelerating access to gro…
ПОДКАСТ ТЪРСАЧКА
Можете да използвате нашия уебсайт, за да търсите3,822,740подкасти и195,633,529епизоди по хора, места или теми.
Инвестицията в знания носи най-добра доходност, затова слушам подкасти.
‐ Benjamin "Llamacorn" Franklin
РЕДАКТИРАНЕ
Благодарим Ви, че помогате да поддържаме базата данни за подкастове актуална.
